During past influenza outbreaks, governments spent billions stockpiling antivirals like Tamiflu (oseltamivir). A Cochrane review later revealed that key claims about the drug’s effectiveness were supported largely by unpublished trial data. Under pressure from the BMJ’s first open data campaign, manufacturers finally released the full data set, only to reveal no solid evidence that Tamiflu prevented respiratory complications. This is far from an isolated case; an estimated 60–80% of clinical trials remain unpublished, leaving critical gaps in the literature. These practices undermine scientific progress, compromise scientific integrity and erode public trust.
What are null and negative results?
Negative and null results occur when a study does not show the expected effect either indicating no effect or an effect in the opposite direction to what was expected.
Why publishing negative results matters
Research is incomplete until it is shared. Publishing both positive and negative results is essential for advancing science and ensuring research transparency and integrity. When findings, especially negative ones, are openly reported, other researchers can replicate, challenge, or build on that work. This helps address the replication crisis, which is the growing concern that a large number of published scientific works are unable to be reproduced or verified. It also helps reduce wasted time, effort, and funding.
Some journals recognise the need to publish negative results. PLOS encourages researchers to publish their negative and null results. One has taken it to the extreme, Journal of Articles in Support of the Null Hypothesis, dedicated entirely to publishing null results.
How negative results drive scientific progress
Negative findings still contribute meaningfully to the scientific record. When studies are properly designed and conducted, a negative result still warrants explanation and analysis.
These outcomes help refine theories, rule out ineffective avenues, and inform the design of future experiments. In this way, they become building blocks of scientific progress. For example, gastritis and ulcers were thought to be caused by emotional stress and spicy food. Early reports noted curved spiral bacteria in the stomach but these findings were largely ignored. Barry Marshall and Robin Warren conducted further research, discovering the majority of patients with peptic ulcers had these curved bacteria in gastric biopsies. Initially, they were unable to culture any of these spiral bacteria, now known as Helicobacter pylori, until prolonged culture led to its growth. Without an animal model, Marshall famously drank a culture of the organism leading to gastritis and proving its role in peptic ulcer disease.
The cost of publication bias
Publication bias is the tendency to publish positive results more often than negative ones, which distorts the evidence base. This has serious consequences:
- Skewed meta-analyses and misleading conclusions
- Misleading clinical and policy decisions
- Wasted research resources
Inclusion of unpublished negative studies improves the accuracy of systematic reviews, making them more reliable for clinical and policy decisions.
When researchers know their work can be published regardless of outcome, there is less pressure to manipulate or selectively report data. That fosters greater transparency and reinforces scientific integrity.
Conclusion
Negative or null results are not failures of research. They are essential to the scientific process and have a meaningful contribution.
Recognising their value and supporting their publication is crucial to building not only a reliable but also a transparent body of evidence. It is the responsibility of the entire research community to ensure that all findings, regardless of outcome, are made readily available.
The latest Declaration of Helsinki states:
“Negative and inconclusive as well as positive results must be published or otherwise made publicly available.”
Researchers have a commitment to reporting their findings honestly, regardless of outcome. Editors and reviewers must advocate for the value of all findings, regardless of result.
Learn more about Elion here.
Photo credit: Image taken from freepik.
